Biomarkers of ovarian response: current and future applications.
about
Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve MarkersMaximizing the clinical utility of antimüllerian hormone testing in women's healthIndividualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceThe Bologna criteria for poor ovarian response: a contemporary critical appraisalWhat threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraceptionWhich cut-off value of serum anti-Müllerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis.Anti-Müllerian hormone deficiency in females with Fanconi anemia.Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropinOvarian Damages Produced by Aerosolized Fine Particulate Matter (PM2.5) Pollution in Mice: Possible Protective Medications and MechanismsLow-cost in vitro fertilization: current insights.Ovarian reserve markers and assisted reproductive technique (ART) outcomes in women with advanced endometriosis.Assessment of ovarian reserve using anti-Müllerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review.Reclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceiveReduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromesOngoing pregnancy rates in women with low and extremely low AMH levels. A multivariate analysis of 769 cycles.Long-term follow-up of females with unbalanced X;Y translocations-reproductive and nonreproductive consequences.The TP73 gene polymorphism (rs4648551, A>G) is associated with diminished ovarian reserveThe Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation.Simultaneous gene deletion of gata4 and gata6 leads to early disruption of follicular development and germ cell loss in the murine ovary.Cell-free DNA in Human Follicular Microenvironment: New Prognostic Biomarker to Predict in vitro Fertilization Outcomes.Cut-Off Levels of Anti-Mullerian Hormone for The Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome.Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based NomogramCirculating microRNAs in follicular fluid, powerful tools to explore in vitro fertilization processPIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndromeAnti Mullerian Hormone: Ovarian response indicator in young patients receiving Long GnRH Agonist Protocol for Ovarian Stimulation.No common denominator: a review of outcome measures in IVF RCTs.A comparative study on the results of agonist and antagonist protocols based on serum AMH levels in patients undergoing intracytoplasmic sperm injection.Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone.The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis.Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response.Current concepts in premature ovarian insufficiency.Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing.Exposure to modern, widespread environmental endocrine disrupting chemicals and their effect on the reproductive potential of women: an overview of current epidemiological evidence.The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal.Chemotherapy-induced damage to ovary: mechanisms and clinical impact.Usefulness of the Ultrasensitive Anti-Müllerian Hormone Assay for Predicting True Ovarian Reserve.Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis.
P2860
Q26765770-9762310D-A0EA-406A-94F6-D3B96F0636C2Q26822937-5AA6EE2E-39F9-407C-9443-E80A3D67CC85Q26829747-EE36FBDB-4207-4C15-9D2B-3D14CE70FD04Q27021821-5B08EA59-9F66-4D5C-BDD3-281F95471F33Q28275450-09229275-4D0F-404E-9367-B7F10A7A6D40Q28393325-0A00343F-8A3F-4A55-A12C-0EEB763F9DD4Q30766464-8C514027-7DE0-4FAB-9D64-1A11AC5662F6Q33569005-93D84DF0-EE0C-46D1-AF10-720D45198314Q33604947-8852D3A1-EA46-4F48-B62C-84E838487485Q33761614-CB780986-9EA3-4DB9-8440-11174D0409B3Q33776849-09263B6C-0053-43E4-A194-01AE97E11391Q34110154-9C5B9C5D-DB79-4C14-8661-66CC24036C5EQ34706985-9A22577E-94E5-4A8B-8BE0-C0685BB6D624Q34761841-3E235EEC-3A8D-4E12-996D-2585215AF64AQ34902729-96930276-F2D2-4354-9300-99C13DB877A7Q35055118-6A02094D-3F8C-42FE-BEA3-B09BC5FCFEECQ35074369-D608FACB-EFD2-4AAE-B153-6C99BC6529BBQ35141067-A5F9BE5A-C2DD-4AEA-A416-B15BBA1E53CFQ35202859-3BA1CE38-4535-4CAC-90ED-DA88DD39465CQ35226815-C78BF771-D1D8-442C-99F1-80B157ED97ABQ35617232-79F02748-07AB-447A-82B5-B784BE6F593EQ35750317-3C9CC8F4-2CC1-4431-9E04-D5906DA2A9BDQ35898934-07BCCC7E-EF07-42D2-A0FB-B4F67622214BQ36116355-082F9862-3733-46FC-B50B-8C892990341DQ36824056-DE921755-A56E-4FD5-990A-013D2B52EDF6Q37179427-93C85069-63D3-4A73-8F6F-4BF4C953BEB8Q37244112-AD9AA0B4-0F13-43B5-9A35-16EC08D58DCEQ37540833-55A5C8CB-11D7-48C0-8F57-A6660B7064C9Q37547081-2552CE42-7F20-4FF2-8FFA-B948D9F039EEQ37593698-AC904B05-DD2C-4B6A-912A-594150B646A2Q38236206-EABCFFF8-81C8-4A86-86EE-DE038FAB7676Q38250303-84939A14-9FDE-4B47-8E55-CE2B2219DCDFQ38285639-3ACF8C4D-3E84-4745-A6B8-58852CAB7EA7Q38380077-FE26BAD1-A2AD-4F16-B3A3-2A3FDAA36CEAQ38602025-40F8EDDE-67F5-474F-BD4F-6E619B3F3A3DQ38652297-E27E5959-D285-49D1-9B4A-44A64CAD42DDQ38804048-BF0D8809-AD86-4A4C-9FC3-81764D1CA388Q38842887-AB24FD6D-7BD6-4407-8190-E7161C28B2F7Q38937881-FDFE3BBB-A554-449E-AA07-E24977256EBAQ38963455-18DBD6A7-7C4A-4B45-B39C-CD8E39BB5FE5
P2860
Biomarkers of ovarian response: current and future applications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biomarkers of ovarian response: current and future applications.
@en
type
label
Biomarkers of ovarian response: current and future applications.
@en
prefLabel
Biomarkers of ovarian response: current and future applications.
@en
P1476
Biomarkers of ovarian response: current and future applications.
@en
P304
P356
10.1016/J.FERTNSTERT.2012.11.051
P407
P577
2013-01-08T00:00:00Z